Genelux FY 2025 net loss widens 7.62% to USD 32.15 million

Reuters03-20 04:08

Genelux FY 2025 net loss widens 7.62% to USD 32.15 million

Genelux published its Annual Report on Form 10-K for the fiscal year ended Dec. 31, 2025.
Net loss widened 7.6% to USD 32.15 million, while revenue was USD 8,000.
Research and development expense rose 5.5% to USD 19.85 million, driven primarily by higher clinical and regulatory costs tied to the Phase 3 On Prime/GOG-3076 registration trial.
General and administrative expense increased 5.2% to USD 13.37 million, mainly reflecting higher employee compensation from annual salary increases and headcount changes, partly offset by lower consulting services.
Cash, cash equivalents, restricted cash and marketable securities totaled USD 14.6 million at year-end; management said this, plus USD 18.5 million of net proceeds from a January 2026 stock offering, is expected to fund operations into the first quarter of 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genelux Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-011616), on March 19, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2620127640?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-20 04:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620127640","market":"fut","top_or_hot":-1,"title":"Genelux FY 2025 net loss widens 7.62% to USD 32.15 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Genelux FY 2025 net loss widens 7.62% to USD 32.15 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Genelux published its Annual Report on Form 10-<a href=\"https://laohu8.com/S/TKKD.SI\">K</a> for the fiscal year ended Dec. 31, 2025.\n        </li>\n<li>\n          Net loss widened 7.6% to USD 32.15 million, while revenue was USD 8,000.\n        </li>\n<li>\n          Research and development expense rose 5.5% to USD 19.85 million, driven primarily by higher clinical and regulatory costs tied to the Phase 3 On Prime/GOG-3076 registration trial.\n        </li>\n<li>\n          General and administrative expense increased 5.2% to USD 13.37 million, mainly reflecting higher employee compensation from annual salary increases and headcount changes, partly offset by lower consulting services.\n        </li>\n<li>\n          Cash, cash equivalents, restricted cash and marketable securities totaled USD 14.6 million at year-end; management said this, plus USD 18.5 million of net proceeds from a January 2026 stock offering, is expected to fund operations into the first quarter of 2027.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/GNLX\">Genelux Corporation</a> published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-011616), on March 19, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Genelux FY 2025 net loss widens 7.62% to USD 32.15 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGenelux FY 2025 net loss widens 7.62% to USD 32.15 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-20 04:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Genelux FY 2025 net loss widens 7.62% to USD 32.15 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Genelux published its Annual Report on Form 10-<a href=\"https://laohu8.com/S/TKKD.SI\">K</a> for the fiscal year ended Dec. 31, 2025.\n        </li>\n<li>\n          Net loss widened 7.6% to USD 32.15 million, while revenue was USD 8,000.\n        </li>\n<li>\n          Research and development expense rose 5.5% to USD 19.85 million, driven primarily by higher clinical and regulatory costs tied to the Phase 3 On Prime/GOG-3076 registration trial.\n        </li>\n<li>\n          General and administrative expense increased 5.2% to USD 13.37 million, mainly reflecting higher employee compensation from annual salary increases and headcount changes, partly offset by lower consulting services.\n        </li>\n<li>\n          Cash, cash equivalents, restricted cash and marketable securities totaled USD 14.6 million at year-end; management said this, plus USD 18.5 million of net proceeds from a January 2026 stock offering, is expected to fund operations into the first quarter of 2027.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/GNLX\">Genelux Corporation</a> published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-011616), on March 19, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GNLX","symbol_name":"Genelux Corporation","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDL6MVGZX:1","article_id":"2620127640","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620127640","pubTimestamp":1773950932,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Genelux published its Annual Report on Form 10-K for the fiscal year ended Dec. 31, 2025.Net loss widened 7.6% to USD 32.15 million, while revenue was USD 8,000.Research and development expense rose 5.5% to USD 19.85 million, driven primarily by higher clinical and regulatory costs tied to the Phase 3 On Prime/GOG-3076 registration trial.General and administrative expense increased 5.2% to USD 13.37 million, mainly reflecting higher employee compensation from annual salary increases and headcount changes, partly offset by lower consulting services.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genelux Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Ret","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GNLX":"Genelux Corporation","BK4139":"生物科技"},"translate_title":"Genelux 2025财年净亏损扩大7.62%至3215万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GNLX":0.9},"content_text":"Genelux FY 2025 net loss widens 7.62% to USD 32.15 million\n    \n\n\n          Genelux published its Annual Report on Form 10-K for the fiscal year ended Dec. 31, 2025.\n        \n\n          Net loss widened 7.6% to USD 32.15 million, while revenue was USD 8,000.\n        \n\n          Research and development expense rose 5.5% to USD 19.85 million, driven primarily by higher clinical and regulatory costs tied to the Phase 3 On Prime/GOG-3076 registration trial.\n        \n\n          General and administrative expense increased 5.2% to USD 13.37 million, mainly reflecting higher employee compensation from annual salary increases and headcount changes, partly offset by lower consulting services.\n        \n\n          Cash, cash equivalents, restricted cash and marketable securities totaled USD 14.6 million at year-end; management said this, plus USD 18.5 million of net proceeds from a January 2026 stock offering, is expected to fund operations into the first quarter of 2027.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genelux Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-011616), on March 19, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2620127640","isCrawlerRequest":true}